Lataa...
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
Hodgkin lymphoma (HL) relapsing after allogeneic stem cell transplantation (alloSCT) presents a major clinical challenge. In the present investigation, we evaluated brentuximab vedotin, a CD30-directed Ab-drug conjugate, in 25 HL patients (median age, 32 years; range, 20-56) with recurrent disease a...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3731651/ https://ncbi.nlm.nih.gov/pubmed/22510871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-397893 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|